{"id":1216095,"date":[{"year":1999,"month":9,"day":3}],"page":"8","source":"本报","region":"","masthead":"文汇财经·投资新闻·广告","special_issue":"文汇财经","column":"财经快讯","genre":"","count":"228","ytitle":"","mtitle":"“双鹤药业”加紧开发新药","ftitle":"","authors":[],"text":[{"type":"paragraph","text":"本报讯　北京双鹤药业股份有限公司(600062)新近推出的第三代喹诺酮类新药利复星，获得医药界人士的认同，目前正在迅速推广，这是该公司副总经理金忠毅昨天在沪披露的。"},{"type":"paragraph","text":"作为医药类老牌绩优公司，“双鹤药业”以其崭新的营销体系，积极推广新药“利复星”、“奥复星”等，并使之成为今年和以后主要利润增长点。据悉，该两种新药今年产值将超过2亿元。“利复星”的成功面市，也标志着我国制药工业的某些领域，已超过国际水平。"}]}